Literature DB >> 15541030

Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection.

V Meraldi1, I Nebié, A B Tiono, D Diallo, E Sanogo, M Theisen, P Druilhe, G Corradin, R Moret, B S Sirima.   

Abstract

A longitudinal study was undertaken in Burkina Faso among 293 children aged 6 months to 9 years in order to determine the correlation between an antibody response to several individual malarial antigens and malarial infection. It was found that the presence of a positive antibody response at the beginning of the rainy season to three long synthetic peptides corresponding to Plasmodium falciparum Exp-1 101-162, MSP-3 154-249 and GLURP 801-920 but not to CSP 274-375 correlated with a statistically significant decrease in malarial infection during the ongoing transmission season. The simultaneous presence of an antibody response to more than one antigen is indicative of a lower frequency of malarial infection. This gives scientific credibility to the notion that a successful malaria vaccine should contain multiple antigens.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15541030     DOI： 10.1111/j.0141-9838.2004.00705.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN： 0141-9838            Impact factor:   2.280


  36 in total

1.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

2.  Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate.

Authors:  Andreas Martin Lisewski; Joel P Quiros; Caroline L Ng; Anbu Karani Adikesavan; Kazutoyo Miura; Nagireddy Putluri; Richard T Eastman; Daniel Scanfeld; Sam J Regenbogen; Lindsey Altenhofen; Manuel Llinás; Arun Sreekumar; Carole Long; David A Fidock; Olivier Lichtarge
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

3.  Genetic Diversity of the Plasmodium falciparum Glutamate-Rich Protein R2 Region Before and Twelve Years after Introduction of Artemisinin Combination Therapies among Febrile Children in Nigeria.

Authors:  Christian N Nguetse; Johnson Adeyemi Ojo; Charles Nchotebah; Moses Nkechukwu Ikegbunam; Christian G Meyer; Bolaji N Thomas; Thirumalaisamy P Velavan; Olusola Ojurongbe
Journal:  Am J Trop Med Hyg       Date:  2018-01-18       Impact factor: 2.345

4.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

5.  Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities.

Authors:  Danica A Helb; Kevin K A Tetteh; Philip L Felgner; Jeff Skinner; Alan Hubbard; Emmanuel Arinaitwe; Harriet Mayanja-Kizza; Isaac Ssewanyana; Moses R Kamya; James G Beeson; Jordan Tappero; David L Smith; Peter D Crompton; Philip J Rosenthal; Grant Dorsey; Christopher J Drakeley; Bryan Greenhouse
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

6.  Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development.

Authors:  Jack S Richards; Thangavelu U Arumugam; Linda Reiling; Julie Healer; Anthony N Hodder; Freya J I Fowkes; Nadia Cross; Christine Langer; Satoru Takeo; Alex D Uboldi; Jennifer K Thompson; Paul R Gilson; Ross L Coppel; Peter M Siba; Christopher L King; Motomi Torii; Chetan E Chitnis; David L Narum; Ivo Mueller; Brendan S Crabb; Alan F Cowman; Takafumi Tsuboi; James G Beeson
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

7.  Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.

Authors:  Issa Nebie; Amidou Diarra; Alphonse Ouedraogo; Issiaka Soulama; Edith C Bougouma; Alfred B Tiono; Amadou T Konate; Roma Chilengi; Michael Theisen; Daniel Dodoo; Ed Remarque; Samuel Bosomprah; Paul Milligan; Sodiomon B Sirima
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

8.  New antigens for a multicomponent blood-stage malaria vaccine.

Authors:  Faith H Osier; Margaret J Mackinnon; Cécile Crosnier; Gregory Fegan; Gathoni Kamuyu; Madushi Wanaguru; Edna Ogada; Brian McDade; Julian C Rayner; Gavin J Wright; Kevin Marsh
Journal:  Sci Transl Med       Date:  2014-07-30       Impact factor: 17.956

Review 9.  The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.

Authors:  Freya J I Fowkes; Jack S Richards; Julie A Simpson; James G Beeson
Journal:  PLoS Med       Date:  2010-01-19       Impact factor: 11.069

10.  The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.

Authors:  David Courtin; Mayke Oesterholt; Harm Huismans; Kwadwo Kusi; Jacqueline Milet; Cyril Badaut; Oumar Gaye; Will Roeffen; Edmond J Remarque; Robert Sauerwein; André Garcia; Adrian J F Luty
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.